One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most ...

A direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention the side effects of the drugs.